Clinical trial · Observational
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Adjuvant Melanoma Setting
NCT05079113CI-TRIAL-00079204completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage III Melanoma | Melanoma | CURATED_BROADER | 0.78 |
| Stage IV Cutaneous Melanoma | Cutaneous Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Identify a pattern for gene recognition of cancer recurrence earlier than standard of care.
- timeFrame
- samples taken at baseline, 3 months, 6 months and 18 months.
- description
- Genomic sequencing of 40+ ctDNA genes will be analyzed to identify genetic alterations correlating with the development of recurrence in melanoma.
Secondary outcomes (1)
- measure
- Analyze the genetic pathway associated with cancer recurrence and biologic information.
- timeFrame
- samples taken at baseline, 3 months, 6 months and 18 months.
- description
- The sequencing data will be analyzed against established determinants of cancer biology in clinically relevant melanoma variants identified via analysis of The Cancer Genome Atlas database.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 * Confirmed fully resected Stage IIIb-IV cutaneous melanoma; including patients treated neoadjuvantly within three months prior to resection. Exclusion Criteria: • Treatment plan inconsistent with the standard of care systemic adjuvant therapies 4.0 Study Design
References
Publications (0)
Data not yet available
No reference posted for this study.